Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD. - Test2 - elhamkhani - TriplyDB

Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD.

Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD.

http://www.wikidata.org/entity/Q37803420

about

Amphetamine, past and present--a pharmacological and clinical perspective Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options Current approaches in tamper-resistant and abuse-deterrent formulations.Abuse-deterrent formulations: part 2: commercial products and proprietary technologies.Nonmedical Use and Diversion of ADHD Stimulants Among U.S. Adults Ages 18-49: A National Internet Survey.

P2860

Q22241826-6909C0B8-5173-4564-8961-7F35C24265AA Q34286130-AC26DE7E-FA2F-49FC-87D8-9D6C7A9C1EED Q38005778-B9E81F42-FD12-4D3C-84D5-5195471D0AE0 Q38271152-DE802CC3-96F6-448C-8E85-527AAC212C23 Q48204458-CDBB178C-4497-4E31-9041-CCDF2847EB58

P2860

Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD.

http://www.wikidata.org/entity/Q37803420

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 October 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD.

@en

Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD.

@nl

type

label

Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD.

@en

Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD.

@nl

prefLabel

Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD.

@en

Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD.

@nl

P1433

Q37803420-534CD0DD-E66A-45D1-84C9-65A2F601ADB5

P1476

Q37803420-66B167E8-5548-40D1-A14F-1B2E53A49F0E

P2093

Q37803420-0E91BD3F-712E-41DD-982B-FE153B7F9F94

Q37803420-87FB5B3F-4167-4CD2-8E22-7AC873C7C61E

P2860

Q37803420-03BF93B7-E5E6-4B63-B8E3-C96CA5078B94

Q37803420-0B8CD317-FDC5-4B62-9C71-009FDE7CBC2E

Q37803420-203E21A6-0E67-4F32-8D35-C3E2261A65EE

Q37803420-2076EDD8-440F-4AC1-883D-14133DC9353A

Q37803420-2A82245E-FE89-4E46-8B8C-8F929F5655EF

Q37803420-32B0C5DE-9E19-4A7C-AF2C-1389567C341F

Q37803420-3B8E73D1-49D5-4549-96EB-E9B98003ADC3

Q37803420-43CF3190-3055-47C4-BE20-8D2CBA2428C2

Q37803420-5410FA9A-3305-421B-A7CF-4F4A4D394C67

Q37803420-57960157-4C0D-4E9C-B108-A29E21AB8EBB

P304

Q37803420-7BA01F1F-B6CF-40C3-9C3F-66EEFEFA6904

P31

Q37803420-89A11CC6-1919-4AC8-B4C8-E0B979BBA382

P356

Q37803420-68A442CD-6C79-46A5-A567-54E0C5E6F7BE

P407

Q37803420-2987BCE6-A830-4C15-9B6C-229F4FDE325B

P433

Q37803420-0F651520-1199-4813-A374-331C5AAAB99D

P478

Q37803420-EF461B13-F2C4-4ACB-948E-6517ECA5F88F

P577

Q37803420-A16AD9E3-D993-441D-9889-2D33723EC4F0

P698

Q37803420-34A57059-7CBE-4D29-916D-E1C5DE05BFE7

P356

14656566.2010.531009

P1433

Expert Opinion on Pharmacotherapy

P1476

Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD.

@en

P2093

Rachel E Dew

http://www.w3.org/2001/XMLSchema#string

Scott H Kollins

http://www.w3.org/2001/XMLSchema#string

P2860

Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication

Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse

New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential.

Alopecia following initiation of lisdexamfetamine in a pediatric patient.

A clinical review of outcomes of the multimodal treatment study of children with attention-deficit/hyperactivity disorder (MTA).

Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.

Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children.

Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study.

P304

2907-2913

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2010.531009

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20979573

http://www.w3.org/2001/XMLSchema#string